The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Genome Sequencing Market Research Report 2024
Synopsis
Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.
The global Cancer Genome Sequencing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations.
This report aims to provide a comprehensive presentation of the global market for Cancer Genome Sequencing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Genome Sequencing.
Report Scope
The Cancer Genome Sequencing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Genome Sequencing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Genome Sequencing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
GE Healthcare Life Sciences
Johnson & Johnson
LI-COR Biosciences
Abbott Laboratories
Beckman Coulter
Bayer
Hamilton Thorne Biosciences
Integrated DNA Technologies
Microchip Biotechnologies
Myriad Genetics
Commonwealth Biotechnologies
ZS Genetics
Pacific Biosciences
Segment by Type
Second Generation
Third Generation
Segment by Application
Treatment
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Genome Sequencing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.
The global Cancer Genome Sequencing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations.
This report aims to provide a comprehensive presentation of the global market for Cancer Genome Sequencing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Genome Sequencing.
Report Scope
The Cancer Genome Sequencing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Genome Sequencing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Genome Sequencing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
GE Healthcare Life Sciences
Johnson & Johnson
LI-COR Biosciences
Abbott Laboratories
Beckman Coulter
Bayer
Hamilton Thorne Biosciences
Integrated DNA Technologies
Microchip Biotechnologies
Myriad Genetics
Commonwealth Biotechnologies
ZS Genetics
Pacific Biosciences
Segment by Type
Second Generation
Third Generation
Segment by Application
Treatment
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Genome Sequencing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Genome Sequencing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Second Generation
1.2.3 Third Generation
1.3 Market by Application
1.3.1 Global Cancer Genome Sequencing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Treatment
1.3.3 Research
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Genome Sequencing Market Perspective (2019-2030)
2.2 Cancer Genome Sequencing Growth Trends by Region
2.2.1 Global Cancer Genome Sequencing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Genome Sequencing Historic Market Size by Region (2019-2024)
2.2.3 Cancer Genome Sequencing Forecasted Market Size by Region (2025-2030)
2.3 Cancer Genome Sequencing Market Dynamics
2.3.1 Cancer Genome Sequencing Industry Trends
2.3.2 Cancer Genome Sequencing Market Drivers
2.3.3 Cancer Genome Sequencing Market Challenges
2.3.4 Cancer Genome Sequencing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Genome Sequencing Players by Revenue
3.1.1 Global Top Cancer Genome Sequencing Players by Revenue (2019-2024)
3.1.2 Global Cancer Genome Sequencing Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Genome Sequencing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Genome Sequencing Revenue
3.4 Global Cancer Genome Sequencing Market Concentration Ratio
3.4.1 Global Cancer Genome Sequencing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Genome Sequencing Revenue in 2023
3.5 Cancer Genome Sequencing Key Players Head office and Area Served
3.6 Key Players Cancer Genome Sequencing Product Solution and Service
3.7 Date of Enter into Cancer Genome Sequencing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Genome Sequencing Breakdown Data by Type
4.1 Global Cancer Genome Sequencing Historic Market Size by Type (2019-2024)
4.2 Global Cancer Genome Sequencing Forecasted Market Size by Type (2025-2030)
5 Cancer Genome Sequencing Breakdown Data by Application
5.1 Global Cancer Genome Sequencing Historic Market Size by Application (2019-2024)
5.2 Global Cancer Genome Sequencing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Genome Sequencing Market Size (2019-2030)
6.2 North America Cancer Genome Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Genome Sequencing Market Size by Country (2019-2024)
6.4 North America Cancer Genome Sequencing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Genome Sequencing Market Size (2019-2030)
7.2 Europe Cancer Genome Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Genome Sequencing Market Size by Country (2019-2024)
7.4 Europe Cancer Genome Sequencing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Genome Sequencing Market Size (2019-2030)
8.2 Asia-Pacific Cancer Genome Sequencing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Genome Sequencing Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Genome Sequencing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Genome Sequencing Market Size (2019-2030)
9.2 Latin America Cancer Genome Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Genome Sequencing Market Size by Country (2019-2024)
9.4 Latin America Cancer Genome Sequencing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Genome Sequencing Market Size (2019-2030)
10.2 Middle East & Africa Cancer Genome Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Genome Sequencing Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Genome Sequencing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Cancer Genome Sequencing Introduction
11.1.4 Agilent Technologies Revenue in Cancer Genome Sequencing Business (2019-2024)
11.1.5 Agilent Technologies Recent Development
11.2 GE Healthcare Life Sciences
11.2.1 GE Healthcare Life Sciences Company Detail
11.2.2 GE Healthcare Life Sciences Business Overview
11.2.3 GE Healthcare Life Sciences Cancer Genome Sequencing Introduction
11.2.4 GE Healthcare Life Sciences Revenue in Cancer Genome Sequencing Business (2019-2024)
11.2.5 GE Healthcare Life Sciences Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Cancer Genome Sequencing Introduction
11.3.4 Johnson & Johnson Revenue in Cancer Genome Sequencing Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 LI-COR Biosciences
11.4.1 LI-COR Biosciences Company Detail
11.4.2 LI-COR Biosciences Business Overview
11.4.3 LI-COR Biosciences Cancer Genome Sequencing Introduction
11.4.4 LI-COR Biosciences Revenue in Cancer Genome Sequencing Business (2019-2024)
11.4.5 LI-COR Biosciences Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Company Detail
11.5.2 Abbott Laboratories Business Overview
11.5.3 Abbott Laboratories Cancer Genome Sequencing Introduction
11.5.4 Abbott Laboratories Revenue in Cancer Genome Sequencing Business (2019-2024)
11.5.5 Abbott Laboratories Recent Development
11.6 Beckman Coulter
11.6.1 Beckman Coulter Company Detail
11.6.2 Beckman Coulter Business Overview
11.6.3 Beckman Coulter Cancer Genome Sequencing Introduction
11.6.4 Beckman Coulter Revenue in Cancer Genome Sequencing Business (2019-2024)
11.6.5 Beckman Coulter Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Cancer Genome Sequencing Introduction
11.7.4 Bayer Revenue in Cancer Genome Sequencing Business (2019-2024)
11.7.5 Bayer Recent Development
11.8 Hamilton Thorne Biosciences
11.8.1 Hamilton Thorne Biosciences Company Detail
11.8.2 Hamilton Thorne Biosciences Business Overview
11.8.3 Hamilton Thorne Biosciences Cancer Genome Sequencing Introduction
11.8.4 Hamilton Thorne Biosciences Revenue in Cancer Genome Sequencing Business (2019-2024)
11.8.5 Hamilton Thorne Biosciences Recent Development
11.9 Integrated DNA Technologies
11.9.1 Integrated DNA Technologies Company Detail
11.9.2 Integrated DNA Technologies Business Overview
11.9.3 Integrated DNA Technologies Cancer Genome Sequencing Introduction
11.9.4 Integrated DNA Technologies Revenue in Cancer Genome Sequencing Business (2019-2024)
11.9.5 Integrated DNA Technologies Recent Development
11.10 Microchip Biotechnologies
11.10.1 Microchip Biotechnologies Company Detail
11.10.2 Microchip Biotechnologies Business Overview
11.10.3 Microchip Biotechnologies Cancer Genome Sequencing Introduction
11.10.4 Microchip Biotechnologies Revenue in Cancer Genome Sequencing Business (2019-2024)
11.10.5 Microchip Biotechnologies Recent Development
11.11 Myriad Genetics
11.11.1 Myriad Genetics Company Detail
11.11.2 Myriad Genetics Business Overview
11.11.3 Myriad Genetics Cancer Genome Sequencing Introduction
11.11.4 Myriad Genetics Revenue in Cancer Genome Sequencing Business (2019-2024)
11.11.5 Myriad Genetics Recent Development
11.12 Commonwealth Biotechnologies
11.12.1 Commonwealth Biotechnologies Company Detail
11.12.2 Commonwealth Biotechnologies Business Overview
11.12.3 Commonwealth Biotechnologies Cancer Genome Sequencing Introduction
11.12.4 Commonwealth Biotechnologies Revenue in Cancer Genome Sequencing Business (2019-2024)
11.12.5 Commonwealth Biotechnologies Recent Development
11.13 ZS Genetics
11.13.1 ZS Genetics Company Detail
11.13.2 ZS Genetics Business Overview
11.13.3 ZS Genetics Cancer Genome Sequencing Introduction
11.13.4 ZS Genetics Revenue in Cancer Genome Sequencing Business (2019-2024)
11.13.5 ZS Genetics Recent Development
11.14 Pacific Biosciences
11.14.1 Pacific Biosciences Company Detail
11.14.2 Pacific Biosciences Business Overview
11.14.3 Pacific Biosciences Cancer Genome Sequencing Introduction
11.14.4 Pacific Biosciences Revenue in Cancer Genome Sequencing Business (2019-2024)
11.14.5 Pacific Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
